The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Real-world data on chlormethine gel for mycosis fungoides
Marios Koumourtzis, MD, University of Athens Medical School, Andreas Syggros Hospital, Athens, Greece, talks on the need for more real-world data on the use of chlormethine gel for the treatment of mycosis fungoides, a subtype of cutaneous T-cell lymphoma (CTCL). Dr Koumourtzis reports that chlormethine gel has been shown to have an increasing response rate over time, with over 50% of patients achieving a complete repose after 9 months in a Greek study. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
